在急性髓性白血病中优化低强度的三重疗法:一本实用指南
Wei-Ying Jen1, Curtis A Lachowiez2, Jennifer Marvin-Peek1
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Blood cancer journal
|November 25, 2025
概括
前线三重组疗法对急性髓性白血病 (AML) 患者有前途,不适合进行密集化疗,改善缓解率. 由于潜在的毒性,仔细调整剂量和监测至关重要.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床药理学 临床药理学
背景情况:
- 基于Venetoclax的双剂是老年或化学疗法不合格患者急性髓性白血病 (AML) 的标准.
- 许多双重治疗的患者随着时间的推移实现了不完全的缓解或复发.
研究的目的:
- 审查AML前线三重组疗法的新兴证据.
- 为在临床实践中实施三重治疗方案提供实际建议.
主要方法:
- 对AML三连治疗的现有临床数据的综述.
- 对剂量表,副作用和药物相互作用的分析.
主要成果:
- 最初的三重治疗方案显示了令人鼓舞的复合完全缓解和可测量的残留疾病负面性率.
- 三重疗法可以为符合条件的患者促进全源干细胞移植.
- 三胞胎与骨髓抑制和细胞衰竭相关的毒性有关.
结论:
- 三重疗法代表了针对特定AML群体的前线治疗策略.
- 临床应用需要仔细考虑剂量调整和毒性管理.
- 了解药物特定的副作用和相互作用对于安全有效的使用至关重要.
相关概念视频
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K


